Industry P Pharmaceutical Executive
Pharmaceutical Executive: October 2026 Interactive Digital Edition
View the Pharmaceutical Executive October 2026 issue in an interactive format.
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry P Pharmaceutical Executive
View the Pharmaceutical Executive October 2026 issue in an interactive format.
Clinical
C&EN Pharmaceuticals
Prediction markets are wagering on clinical trials. Should scientists participate?
Clinical A Applied Clinical Trials
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavio…
Software P Pharmaceutical Executive
As analysis in our October issue explores, we’ve moved beyond fascination with the technology itself and toward tougher questions about purpose, judgment, trust and measurable impact.
Industry
MedTech Dive
Zimmer distributes an exclusive version of Think’s wireless handheld miniature robotic system that works with its Persona knee system.
Industry P Pharmaceutical Commerce
At LogiPharma USA 2026, BMS’s Kevin Cook explains why CMO partnerships must move beyond transactions toward shared goals and KPIs.
Agriculture
CropLife
Switch Bioworks and Bayer partner to advance engineered microbes that boost biological nitrogen fixation and deliver next-generation fertilizer solutions. The post Switch Bioworks Announces Collaboration with Bayer Crop Science to Advance Biological Nitrogen appeared first on Cro…
Software A Asimov Press
Our third book, ‘Making the Modern Laboratory’, is a lavishly illustrated hardcover about the laboratory, and how (nearly) everything in it came to be. Pre-order today.
Industry P pharmaphorum
Boosting biotech in Basel – with Valentina Francia Jonah.Comstock Thu, 15/10/2026 - 14:31
Regulatory B BioPharm International
The FDA expanded ImmunityBio’s Anktiva plus BCG to include patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary-only tumors, extrapolating efficacy from the QUILT-3.032 carcinoma in situ cohort.
Industry
TechCrunch Biotech and Health
Last day to join TechCrunch Disrupt 2026. Join 10,000+ tech leaders for a day of connections and insights. Save 75% on your pass now.
Research P PLOS Biology
by Ran Blekhman In the age of generative artificial intelligence (AI), the assumption that writing a paper requires doing science no longer holds true. Before deciding how to respond to the surge of AI-generated papers, the field needs to state what biology research is actually f…
Agriculture P PLOS Biology
by Freddie King, Juan Carlos Lopez-Agudelo, Christopher Stephens, May Htet Aung, Tarhan Ibrahim, Enoch Lok Him Yuen, Ao Chen, Nick Eilmann, Saskia Jenkins, Cristina Vuolo, Yueh-Ning Swee, Wei-Jia Liu, Samuel Bruty, AmirAli Toghani, Chih-Horng Kuo, Erh-Min Lai, Jiorgos Kourelis, L…
Software P Pharmaceutical Executive
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Regulatory
MHRA
Fake weight loss medicines worth approximately £2 million were seized last night in a raid executed by the Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Police.
Agriculture
AgriBusiness Global
Geopolitical and climate pressures are increasing risks for farmers while global peers gain faster access to new technologies, widening Europe’s resilience gap. The post EU and UK Risk Falling Further Behind Global Agricultural Competitors, Weakening Strategic Autonomy appeared f…
Regulatory B BioPharm International
The FDA expanded Fast Track status for invikafusp alfa, Marengo Therapeutics’ TCR Vβ-targeting antibody-IL-2 fusion protein, from TMB-H colorectal cancer to TMB-H solid tumors regardless of tissue of origin.
Industry
Pharmaceutical Technology
This deal sees Gilead double down on TCEs, following its first bet on the modality through its buyout of autoimmune-focused Ouro Medicines.
Regulatory
EMA Press
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Rasonque (daraxonrasib), an oral treatment for adults with…
Agriculture
AgriBusiness Global
India’s agrochemical industry secures a positive outcome through science-based advocacy and coordinated engagement with government authorities at international negotiations. The post India: PMFAI Successfully Defends Profenofos, Quinalphos and Phenthoate at Rotterdam Convention’s…
Agriculture
CropLife
New location expands local parts and mobile service support while serving Central Kentucky's equine, livestock and agricultural communities. The post AgRevolution Expands Central Kentucky Presence with New Lexington Facility appeared first on CropLife.
Software P Paired Ends
Volume II of a special research topic in AI and Biosecurity
Industry P Pharmaceutical Commerce
In this week's Pharma Pulse, DHL adds six dedicated cold chain air corridors linking Europe and North America to Asia, Walmart rolls out a $0 prescription tier and rare disease Center of Excellence for its US workforce and FDA launches its Rare Disease Framework Initiative.
Industry B BioPharm International
Mirikizumab (Omvoh) achieved comprehensive disease control in 27.7% of UC patients and deep remission in 20.4% with Crohn disease at 1 year.
Industry
PharmaVoice
New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.
Industry
GEN
Sponsored content brought to you by Digital PCR (dPCR) earned its reputation by solving a real problem: it let researchers count nucleic acid molecules directly, without leaning on a standard curve. But […] The post Thirty Million Compartments: Testing Single-Molecule PCR’s Poten…
Industry P pharmaphorum
ImmunityBio bags elusive label extension for Anktiva Phil.Taylor Thu, 15/10/2026 - 12:47
Regulatory B BioPharm International
Nathan Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Research B BioTechniques
At this year’s AACR Annual Meeting, we spoke with numerous scientists about their research, the challenges that they have faced, and the innovative approaches evolving our understanding of cancer and its treatment. Here, we compile advice from scientists working a…
Industry P pharmaphorum
GLP-1 drugs linked to reduced acute schizophrenia episodes Phil.Taylor Thu, 15/10/2026 - 11:38
Regulatory
Pharmaceutical Technology
The tailored framework arrives amid renewed focus on rare diseases across US health agencies.
Industry P pharmaphorum
Roche breast cancer drug Itovebi turned down by NICE Phil.Taylor Thu, 15/10/2026 - 10:41
Software B BLOPIG
For the final project of my PhD in OPIG, I developed the Therapeutic Nanobody Profiler, or ‘TNP’: a tool to characterise nanobody developability analogous to TAP (the Therapeutic Antibody Profiler). TNP uses 6 metrics, tailored to the unique features of nanobodies, to benchmark t…
Clinical
Clinical Trials Arena
This comes as many pharma companies fail to crack the SAD indication, with little innovation seen in the space in recent years. The post Vanda puts anxiety drug’s development on ice after Phase III fail appeared first on Clinical Trials Arena.
Manufacturing B BioProcess International
Axoltis’ drug, NX210c, failed to meet clinical endpoints in a Phase II trial – but the company says other readouts are positive.
Industry
STAT Biotech
On Wall Street, the real trouble for biotech, and the reason for investor angst, lies below the surface.
Industry P Pharmafile
Femtosecond laser imaging has reduced the time needed to assess lung tumour margins from 36 minutes to less than six in a recent study, potentially giving surgeons time to make decisions about the extent of tissue removal during an operation. The study, published in a peer-review…
Industry P pharmaphorum
Changing Faces: Agency, consultancy, and investor hires, August and September 2026 Nicole.Raleigh Thu, 15/10/2026 - 10:16
Clinical
Clinical Trials Arena
Spinogenix has broadened its ongoing Phase IIb/III CLARITY basket trial to include a Phase IIb study of codabakalner in idiopathic ASD. The post Spinogenix adds Phase IIb autism study to CLARITY basket trial appeared first on Clinical Trials Arena.
Regulatory A Applied Clinical Trials
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.